🗓️ Published: May 28, 2025
✍️ By: Prashant Marathe
Tags: CARE Ratings, Q4FY25 results, Singapore NDR, Institutional Investor Meeting, CARE Share Price, Rating Agencies India, B&K Securities, SEBI LODR Compliance

📌 At a Glance

CARE Ratings Ltd (NSE: CARERATING) is all set for a two-day Non-Deal Roadshow (NDR) in Singapore on June 24–25, 2025, organised by B&K Securities. The management will meet institutional investors in a 1×1 and group format. No UPSI will be discussed, they say. But can they convince the Street with only public info and PowerPoint slides?

Meanwhile, the stock closed at ₹1,676, down 1.73% today, in line with the broader midcap selloff.

🏦 What’s the Update?

📢 CARE Ratings filed an exchange intimation on May 28, 2025, under Regulation 30 of SEBI LODR, saying:

• They’ll meet investors in Singapore
• It’s a Non-Deal Roadshow, meaning no fundraising pitch—just goodwill building
• Discussions will stick to publicly available information
• Investor Presentation already uploaded here:
  🔗 Q4 FY25 Investor Deck

✈️ Why Singapore?

Let’s decode:

• Global interest in India’s infra & finance stories is surging. With Bharat Ratings & ICRA also stepping up global investor connect, CARE doesn’t want to be left behind.
• Singapore = Asia’s fund capital, especially for midcap financials.
• CARE’s stock is up ~90% from its 2023 lows. That’s a juicy “Look at our turnaround!” narrative for foreign funds.

But here’s the twist: Unlike big boys like CRISIL (with S&P parentage), CARE still needs to prove its mojo every few quarters.

📊 Quick Financial Snapshot (Q4 FY25)

Verdict: Steady growth, expanding margins. But no fireworks.

🧠 EduInvesting Take

This NDR is like a Tinder date with investors—no commitments, just vibes.

CARE’s pitch will revolve around:

• Consistent PAT growth
• Dividend-paying credibility
• India’s $1.4T infra push needing credible ratings
• Tech investments to stay relevant in a GenAI + ESG obsessed world

But here’s the real question:

Can they grow faster than India’s GDP… or are they just going to ride macro tailwinds?

Because let’s face it: If GDP grows 6.8%, and you grow 7%, that’s not alpha. That’s inflation + luck.

🔍 What Investors Might Ask in Singapore

• “You’ve grown revenue, sure. But where’s the non-rating income?”
• “How do you plan to compete with AI-powered risk platforms?”
• “What’s the strategy post-independence from CARE Advisory & Analytics?”
• “Any acquisitions or consolidation plans?”

(And the most honest one…)

“So, uh, how do you plan to stay relevant when banks mostly use internal ratings now?”

🤔 Should You Care About CARE?

That depends.

If you’re bullish on:

• India’s corporate bond market deepening
• Infra lending cycle finally waking up
• SEBI’s push for credit rating reforms
  Then yes, CARE has legs.

But if you believe the new-age rating game is data + AI + automation, you might be asking: “Where’s CARE’s ChatGPT?”

🎯 What to Watch Next

• Stock reaction post-NDR: Smart money often leaves clues.
• Management commentary on AI, ESG, and tech-led rating models.
• Any soft guidance on growth outlook or capital allocation.
• Next quarter’s revenue split – how much is still coming from bread-and-butter vs diversification?

📉 Market Reaction Today

Nothing too dramatic. But post-NDR bump? Entirely possible.

🧵 Final Words

CARE Ratings isn’t here to raise funds, but to raise confidence. The Singapore meetings could set the tone for FY26 visibility.

Until then, it’s all about the slides, smiles, and scripted non-UPSI charm.

Stay tuned. EduInvesting will cover every rating agency’s next move… before they rate you.

🗓️ Published: May 28, 2025
✍️ By: Prashant Marathe
Tags: CARE Ratings, Q4FY25 results, Singapore NDR, Institutional Investor Meeting, CARE Share Price, Rating Agencies India, B&K Securities, SEBI LODR Compliance